ReviewCurrent heart failure reports2026
Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewTransthyretin amyloid cardiomyopathy (ATTR-CM) is a type of progressive cardiomyopathy that is characterized by the accumulation of misfolded transthyretin protein within the myocardium. Cardiorenal dysfunction is common among patients with ATTR-CM, and its presence is associated with worse outcomes. As such, monitoring kidney dysfunction has important implications for disease prognostication. There remains an unmet need to better characterize renal biomarkers to enhance risk stratification and assessment of treatment response in affected patients. The goal of this review is to detail how cardiorenal dysfunction influences the clinical natural history of ATTR-CM and how it may be modified by treatment. RECENT
findingsAn increasing body of evidence has evaluated the usefulness of various renal biomarkers in ATTR-CM. Beyond traditional measures such as estimated glomerular filtration rate(eGFR), measures of albuminuria, cystatin C, and uromodulin may better reflect glomerular and tubular vulnerability, while congestion related measures such as outpatient diuretic intensification may better capture disease trajectory. Emerging data also suggest that disease modifying therapies and supportive treatments may influence renal function over time. Cardiorenal biomarkers in ATTR-CM may provide insight into the evolving disease biology and the interplay between cardiac dysfunction and kidney injury. As disease modifying therapies become more widely used, incorporating dynamic renal measures (including eGFR trajectories and albuminuria) may refine prognostic precision and support longitudinal assessment of treatment effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.